@article {Diossy2021.02.08.21251199, author = {Miklos Diossy and Viktoria Tisza and Hua Li and Jia Zhou and Zsofia Sztupinszki and Denise Young and Darryl Nousome and Claire Kuo and Yongmei Chen and Reinhard Ebner and Isabell A. Sesterhenn and Joel T. Moncur and Gregory T. Chesnut and Gyorgy Petrovics and Gregory T. Klus and Sandor Spisak and Gabor Valcz and Pier Vitale Nuzzo and Dezso Ribli and Aimilia Schina and Judit B{\"o}rcs{\"o}k and Aurel Prosz and Marcin Krzystanek and Thomas Ried and David Szuts and Salma Kaochar and Shailja Pathania and Alan D. D{\textquoteright}Andrea and Istvan Csabai and Shiv Srivastava and Albert Dobi and Matthew L Freedman and Zoltan Szallasi}, title = {Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles}, elocation-id = {2021.02.08.21251199}, year = {2021}, doi = {10.1101/2021.02.08.21251199}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background African American (AA) men have significantly higher mortality rates from prostate cancer (PC) than individuals of European ancestry (EA). Therapeutically targetable molecular differences may hold the potential to reduce this disparity.Objective To investigate chromodomain helicase DNA-binding protein 1 (CHD1) deletion both as a cause of aggressive disease and therapeutic vulnerability in the prostate cancer of AA men.Design, setting, and participants 91 AA and 109 EA prostate cancer cases were analyzed by fluorescence in situ hybridization (FISH) for the deletion of CHD1. Whole exome and whole genome sequencing data from prostate adenocarcinoma cases were analyzed for mutational signatures from AA and EA individuals.Outcome measurements and statistical analysis Associations with biochemical recurrence were evaluated using Cox proportional hazard regression models. Association between mutational signatures and CHD1 deletion were assessed by Wilcoxon ranked sum tests.Results and limitations Subclonal deletion of CHD1 is nearly three times as frequent in prostate tumors of men than in EA men. CHD1 deletion is associated with some of the homologous recombination deficiency associated mutational signatures in prostate cancer. In a cell line model CHD1 deletion induced 1-10 kb deletions resembling those induced by BRCA2 deficiency. CHD1 deficient cells showed markedly increased sensitivity to both talazoparib and the radiomimetic bleomycin.Conclusions CHD1 is more frequently deleted in the prostate cancer of AA men. This deletion is both associated with and induces mutational signatures characteristic of BRCA2 deficiency. CHD1 deficient prostate cancer is more sensitive to talazoparib or bleomycin treatment.Patient summary Subclonal deletion of CHD1 is more frequent in the prostate cancer of AA men and this could be one of the reasons behind more aggressive disease. CHD1 deletion, however, also constitutes a therapeutic vulnerability to the PARP inhibitor talazoparib. This treatment may significantly improve the outcome of disease in AA men.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Research and Technology Innovation Fund (KTIA_NAP_13-2014-0021 and NAP2-2017-1.2.1-NKP-0002); Breast Cancer Research Foundation (BCRF-17-156 to Z. Szallasi) and the Novo Nordisk Foundation Interdisciplinary Synergy Program Grant (NNF15OC0016584), Det Fri Forskningsrad (award number $\#$7016-00345B; to Z. Szallasi); Department of Defense through the Prostate Cancer Research Program (award number is W81XWH-18-2-0056; to Z. Szallasi, A. Dobi and M.L. Freedman). Z. Szallasi, Z. Sztupinszki and J. Borcsok were supported by Velux Foundation 00018310 grant. S.K. is supported by the Prostate Cancer Foundation (18YOUN09 and 19CHAL07).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study was reviewed and approved by institutional review board (IRB) of Walter Reed National Military Medical Center and Uniformed Services University of the Health Sciences, Bethesda, MD.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Mayo Clinic whole genomes (Decker et al. 2016) are available at dbGaP under accession number phs001105.v1.p1, the DFCI whole genomes are deposited under accession number phs000661.v1.p. The TCGA whole genomes and whole exomes are available through the ICGC and GDC data portals respectively. https://portal.gdc.cancer.gov/ https://dcc.icgc.org/}, URL = {https://www.medrxiv.org/content/early/2021/02/11/2021.02.08.21251199}, eprint = {https://www.medrxiv.org/content/early/2021/02/11/2021.02.08.21251199.full.pdf}, journal = {medRxiv} }